DiscoverThe BioCentury ShowEp. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

Update: 2024-10-18
Share

Description

With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard’s data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-precarious biotech financing landscape.

View full story: https://www.biocentury.com/article/653858

#biotech #biopharma #pharma #lifescience #IPO #capitalmarkets #deals

00:00 - Introduction
02:17 - Capital Markets Outlook
05:18 - M&A
14:37 - Breaking Down Deals
23:44 - Asia

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

BioCentury